Samsung Bioepis Co., Ltd. and Phrontline Biopharma, a clinical-stage biotechnology company advancing a new generation of ...
Preliminary efficacy data, combined with a tolerable safety profile, reinforce the potential of ZW191 in patients with advanced solid tumors, ...
Two poster presentations showcase best- and first-in-class potential of ALX2004, a novel, antibody-drug conjugate (ADC) for the treatment of ...
Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing ...
The 21-valent pneumococcal conjugate vaccine V116 is well tolerated in adults living with HIV and induces immunity to all 21 ...
Preliminary data presented at the AACR-NCI-EORTC conference will provide insights into the potential of ZW191 in patients ...
Daiichi and Merck saw the highest ORR—57.1%—in patients who received the top dose of R-DXd. Yet the drugmakers have opted to take the middle 5.6 mg/kg dose into the phase 3 part of the trial. The ORR ...
The one chip startup building accelerators for something other than AI boasts performance up 10x that of modern GPUs using a ...
AMT-253 is a potential first-in-class MUC18-directed ADC with a proprietary linker-payload design AMT-253 demonstrated a manageable safety profile, consistent with other TOP1-inhibitor based ADCs ...
Samsung Bioepis partners with Chinese Phrontline to jointly develop two ADC drugs Samsung Bioepis to jointly develop two ADC ...
Zocilurtatug pelitecan (zoci), also known as ZL-1310, an investigational antibody-drug conjugate (ADC) that targets the ...
(PRs) among 13 evaluable non-small cell lung cancer (NSCLC) patients (ORR 38%); 1 confirmed PR among 7 breast cancer patients Favorable safety and PK profile, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback